Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Oncolytics's pelareorep to be tested in Phase 2 breast cancer trial » 07:17
06/25/20
06/25
07:17
06/25/20
07:17
ONCY

Oncolytics

$2.03 /

-0.035 (-1.70%)

, INCY

Incyte

$104.37 /

-2.25 (-2.11%)

Oncolytics (ONCY)…

Oncolytics (ONCY) announced a new investigator-sponsored triple-negative breast cancer study to be managed by Rutgers Cancer Institute of New Jersey. The phase 2 trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte's (INCY) anti-PD-1 checkpoint inhibitor retifanlimab in patients with unresectable locally advanced or metastatic TNBC. The IRENE study represents an expansion of Oncolytics' lead breast cancer program into a new disease subtype. Systemic pelareorep administration has the potential to increase the number of patients that are eligible for checkpoint inhibitor therapy

ShowHide Related Items >><<
ONCY Oncolytics
$2.03 /

-0.035 (-1.70%)

INCY Incyte
$104.37 /

-2.25 (-2.11%)

ONCY Oncolytics
$2.03 /

-0.035 (-1.70%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
INCY Incyte
$104.37 /

-2.25 (-2.11%)

06/16/20
Fly Intel: Top five analyst initiations
06/16/20 Benchmark
Benchmark sees Incyte lacking visibility, starts at Hold
06/16/20 Benchmark
Incyte initiated with a Hold at Benchmark
06/04/20 Argus
Incyte price target raised to $124 from $92 at Argus
INCY Incyte
$104.37 /

-2.25 (-2.11%)

INCY Incyte
$104.37 /

-2.25 (-2.11%)

INCY Incyte
$104.37 /

-2.25 (-2.11%)

Hot Stocks
Oncolytics announces dosing of first patient in phase 2 of Bracelet-1 study » 07:12
06/23/20
06/23
07:12
06/23/20
07:12
ONCY

Oncolytics

$1.94 /

-0.05 (-2.51%)

, PFE

Pfizer

$33.11 /

-0.32 (-0.96%)

, MRK

Merck

$76.71 /

-0.9 (-1.16%)

Oncolytics Biotech (ONCY)…

Oncolytics Biotech (ONCY) announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer, or mBC. The study, known as BRACELET-1, is being conducted under a co-development agreement with Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business in the US and Canada as EMD Serono, and Pfizer (PFE). Participants in the study receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with paclitaxel and Merck (MRK) KGaA, Darmstadt, Germany and Pfizer's anti-PD-L1 checkpoint inhibitor, avelumab. The randomized BRACELET-1 study is designed to support the results of a prior successful phase 2 trial that showed a near doubling of overall survival with pelareorep treatment, by demonstrating pelareorep's ability to induce a robust anti-tumor immune response in an identical patient population.

ShowHide Related Items >><<
PFE Pfizer
$33.11 /

-0.32 (-0.96%)

ONCY Oncolytics
$1.94 /

-0.05 (-2.51%)

MRK Merck
$76.71 /

-0.9 (-1.16%)

ONCY Oncolytics
$1.94 /

-0.05 (-2.51%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
PFE Pfizer
$33.11 /

-0.32 (-0.96%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
06/16/20 SVB Leerink
Pfizer initiated with a Market Perform at SVB Leerink
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
MRK Merck
$76.71 /

-0.9 (-1.16%)

06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
PFE Pfizer
$33.11 /

-0.32 (-0.96%)

MRK Merck
$76.71 /

-0.9 (-1.16%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

MRK Merck
$76.71 /

-0.9 (-1.16%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

MRK Merck
$76.71 /

-0.9 (-1.16%)

PFE Pfizer
$33.11 /

-0.32 (-0.96%)

MRK Merck
$76.71 /

-0.9 (-1.16%)

Syndicate
Oncolytics files C$150M mixed securities shelf  17:28
06/08/20
06/08
17:28
06/08/20
17:28
ONCY

Oncolytics

$2.26 /

+0.14 (+6.60%)

 
ShowHide Related Items >><<
ONCY Oncolytics
$2.26 /

+0.14 (+6.60%)

ONCY Oncolytics
$2.26 /

+0.14 (+6.60%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
Hot Stocks
Oncolytics: ePoster published from phase 1b study of pelareorep-carfilzomib » 07:10
05/29/20
05/29
07:10
05/29/20
07:10
ONCY

Oncolytics

$2.45 /

+0.14 (+6.06%)

Oncolytics announced the…

Oncolytics announced the publication of an electronic-poster with clinical proof-of-concept data from the company's phase 1b study in carfilzomib-refractory multiple myeloma patients treated with pelareorep in combination with carfilzomib. Data presented in the ePoster demonstrates that the pelareorep-carfilzomib combination treatment results in selective replication of pelareorep in cancer cells and beneficial induction of an inflamed tumor environment associated with clinical responses. The ePoster was published this morning and will be presented this weekend as part of the American Society of Clinical Oncology Virtual Annual Meeting.

ShowHide Related Items >><<
ONCY Oncolytics
$2.45 /

+0.14 (+6.06%)

ONCY Oncolytics
$2.45 /

+0.14 (+6.06%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
Hot Stocks
Oncolytics presents data from AWARE-1 cancer study » 07:03
05/26/20
05/26
07:03
05/26/20
07:03
ONCY

Oncolytics

$2.57 /

-0.07 (-2.65%)

Oncolytics Biotech…

Oncolytics Biotech announced the publication of an electronic-poster with clinical data from the company's AWARE-1 window-of-opportunity breast cancer study. The data demonstrates a pelareorep-induced adaptive immune response in the tumor microenvironment and the potential of a predictive biomarker to identify patients with breast cancer most likely to respond to pelareorep. The ePoster was published on May 23, and presented over the weekend, as part of the European Society for Medical Oncology Breast Cancer Virtual Meeting. "The preliminary AWARE-1 data showing a pelareorep-induced adaptive immune response in the tumor microenvironment are highly encouraging and strongly support the trial design and rationale," said Dr. Aleix Prat, co-author and lead translational investigator for the AWARE-1 study. "Observed increases in CelTIL, which are associated with a favorable response to treatment, are particularly noteworthy. Additionally, I am especially excited by data supporting the use of T cell clonality as a predictive and prognostic biomarker of pelareorep response, as the ability to accurately identify patients most likely to respond favorably to treatment will facilitate the success of future trials."

ShowHide Related Items >><<
ONCY Oncolytics
$2.57 /

-0.07 (-2.65%)

ONCY Oncolytics
$2.57 /

-0.07 (-2.65%)

05/11/20 RBC Capital
Oncolytics price target lowered to C$6 from C$9 at RBC Capital
01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
Recommendations
Oncolytics price target lowered to C$6 from C$9 at RBC Capital » 12:21
05/11/20
05/11
12:21
05/11/20
12:21
ONCY

Oncolytics

$2.15 /

+0.44 (+25.73%)

RBC Capital analyst…

RBC Capital analyst Douglas Miehm lowered the firm's price target on Oncolytics to C$6 from C$9 and keeps an Outperform rating on the shares following the company's Q1 earnings results.

ShowHide Related Items >><<
ONCY Oncolytics
$2.15 /

+0.44 (+25.73%)

01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
Over a quarter ago
Hot Stocks
Oncolytics expects COVID-19 to impact clinical trial enrollment » 17:17
04/17/20
04/17
17:17
04/17/20
17:17
ONCY

Oncolytics

$1.42 /

+0.01 (+0.71%)

Oncolytics Biotech,…

Oncolytics Biotech, currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, provided an update on the potential impact of COVID-19 on the company's clinical and business operations. The Company's clinical and regulatory teams remain active and are working closely with investigators to identify the most appropriate steps forward for each study. There has been no impact on the continuity of the manufacturing of pelareorep, and Oncolytics is fully capable of supplying pelareorep to all ongoing clinical studies. Although it is too early to determine the absolute effects of the outbreak on specific trial timelines, it is anticipated that COVID-19 will impact clinical trial enrollment timelines to some degree.

ShowHide Related Items >><<
ONCY Oncolytics
$1.42 /

+0.01 (+0.71%)

01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
Hot Stocks
Oncolytics' pelareorep shows positive safety and efficacy results in publication » 07:05
04/02/20
04/02
07:05
04/02/20
07:05
ONCY

Oncolytics

$1.36 /

-0.06 (-4.23%)

Oncolytics, currently…

Oncolytics, currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced clinical data published in a peer-reviewed journal highlighting that the combination of FOLFIRI, bevacizumab and pelareorep was well tolerated, with promising efficacy signals in colorectal cancer patients with KRAS mutated tumors. The article was published on March 10 in Molecular Cancer Therapeutics. The study enrolled 36 patients with KRAS mutation in a dose-escalation trial, of which 30 patients were assessable for response. The combination of FOLFIRI, bevacizumab and pelareorep was well tolerated, with promising signals of efficacy. Six patients received the recommended phase 2 dose, at which a 50% overall response rate and a median overall survival of 25.1 months were observed, which compares favorably to the historical OS of 13.5 months, an 86% improvement. Among 30 evaluable patients, 6 had a partial response and 22 patients had stable disease as their best response, for a clinical benefit rate of 93.3%. Enhanced efficacy elicited by the administration of pelareorep was supported by evidence of an adaptive immune response occurring after each cycle of pelareorep treatment. These immune responses were only seen after pelareorep administration and not with the other medications alone, strongly suggesting that pelareorep is influencing these responses.

ShowHide Related Items >><<
ONCY Oncolytics
$1.36 /

-0.06 (-4.23%)

01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
Hot Stocks
Oncolytics announces assesment of AWARE-1 from Safety Committee » 07:05
03/24/20
03/24
07:05
03/24/20
07:05
ONCY

Oncolytics

$1.14 /

-0.01 (-0.87%)

Oncolytics Biotech…

Oncolytics Biotech announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1. Consistent with the safety run-in with patients receiving pelareorep and Tecentriq, Cohort 1 demonstrated widespread viral replication in the majority of tumors with the creation of a pro-inflammatory effect in the tumor microenvironment. No negative effects to healthy tissue were noted. The Committee evaluated safety parameters from patients participating in the safety run-in phase of the trial, consisting of select patients from cohorts 2 and 3, along with the fully enrolled cohort 1, and determined there were no safety concerns. The Committee also approved an amendment of the study to reduce the dose of Tecentriq to be consistent with the currently approved breast cancer dose of 840mg. The study will continue to enroll patients and the Safety Committee will meet again for an additional pre-planned meeting. Cohorts 1 and 2 represent our target tumor type of HR+ / HER2- and data from these patients will inform the design of the planned phase 3.

ShowHide Related Items >><<
ONCY Oncolytics
$1.14 /

-0.01 (-0.87%)

01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital
Hot Stocks
Oncolytics: Data identifies CEACAM6 as a prospective biomarker for pelareorep » 07:04
01/27/20
01/27
07:04
01/27/20
07:04
ONCY

Oncolytics

$3.25 /

-0.21 (-6.07%)

Oncolytics Biotech…

Oncolytics Biotech announced that a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer. The presentation was delivered at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO in San Francisco. "We have identified another biomarker candidate for pelareorep," said Dr. Rita Laeufle, Chief Medical Officer of Oncolytics Biotech. "These results correlate CEACAM6 levels with long term benefit in patients with pancreatic cancer. We are working with industry and academic colleagues to verify this important finding not only in pancreatic cancer but potentially in other GI indications where this biomarker is linked to clinical outcomes."

ShowHide Related Items >><<
ONCY Oncolytics
$3.25 /

-0.21 (-6.07%)

01/02/20 Roth Capital
Oncolytics price target raised to $9 from $6.80 at Roth Capital
09/04/19
Fly Intel: Top five analyst initiations
09/04/19 Roth Capital
Oncolytics initiated with a Buy at Roth Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.